Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)

Cancer Investigation

Volumn 26, Issue 1, 2008, Pages 81-95

  Schiller, Joan H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti EGFR therapeutics; EGFR; Matuzumab; Pharmacodynamics; Pharmacokinetics; Safety; Tolerability

Indexed keywords

AMYLASE; ANALGESIC AGENT; ANTIPYRETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMMUNOGLOBULIN G1 ANTIBODY; LIVER ENZYME; MATUZUMAB; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; UNINDEXED DRUG; VINDESINE;

ACNE; ADVANCED CANCER; ANAPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; BILE DUCT CARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRY SKIN; ENDOMETRIUM CARCINOMA; ENZYME BLOOD LEVEL; EPIDERMOLYSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FATIGUE; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HYPOMAGNESEMIA; KERATORHEXIS; LETHARGY; LEUKOPENIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAIL INFECTION; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PARONYCHIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM CANCER; REVIEW; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN PRURITUS; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; THROMBOCYTE; TREATMENT OUTCOME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 37849053111     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701511847     Document Type: Review

References (103)

1. Cohen, S. Nobel lecture. epidermal growth factor. Biosci. Rep. 1986, 6 (12), 1017-1028.
2. Masui, H.; Kawamoto, T.; Sato, J.D.; Wolf, B.; Sato, G.; Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984, 44 (3), 1002-1007.
3. Masui, H.; Moroyama, T.; Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. 1986, 46 (11), 5592-5598.
4. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21 (14), 2787-2799.
5. Baselga, J. Why the epidermal growth factor receptor? the rationale for cancer therapy. Oncologist 2002, 7 (Suppl. 4), 2-8.
6. Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23 (11), 2445-2459.
7. Spano, J.P.; Lagorce, C.; Atlan, D.; Milano, G.; et al. Impact Of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005, 16 (1), 102-108.
8. Resnick, M.B.; Routhier, J.; Konkin, T.; Sabo, E.; Pricolo, V.E. Epidermal growth factor receptor, c-met, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin. Cancer Res. 2004, 10 (9), 3069-3075.
9. Mckay, J.A.; Murray, L.J.; Curran, S.; Ross, V.G.; Clark, C.; Murray, G.I.; Cassidy, J.; Mcleod, H.L. Evaluation of the epidermal growth factor receptor (egfr) in colorectal tumours and lymph node metastases. Eur. J. Cancer 2002, 38 (17), 2258-2264.
10. Porebska, I.; Harlozinska, A.; Bojarowski, T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000, 21 (2), 105-115.
11. Giralt, J.; Eraso, A.; Armengol, M.; Rossello, J.; Majo, J.; et al. I. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54 (5), 1460-1465.
12. Torzewski, M.; Sarbia, M.; Verreet, P.; Bittinger, F.; Dutkowski, P.; Heep, H.; Willers, R.; Gabbert, H.E. The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. Anticancer Res. 1997, 17 (5B), 3915-3919.
13. Itakura, Y.; Sasano, H.; Shiga, C.; Furukawa, Y.; Shiga, K.; Mori, S.; Nagura, H. Epidermal growth factor receptor overexpression in esophageal carcinoma. an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994, 74 (3), 795-804.
14. Hanawa, M.; Suzuki, S.; Dobashi, Y.; Yamane, T.; Kono, K.; Enomoto, N.; Ooi, A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 2005, 118, 1173-1180.
15. Yasui, W.; Sumiyoshi, H.; Hata, J.; Kameda, T.; Ochiai, A.; Ito, H.; Tahara, E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988, 48 (1), 137-141.
16. Meert, A.P.; Martin, B.; Delmotte, P.; Berghmans, T.; Lafitte, J.J.; et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur. Respir. J. 2002, 20 (4), 975-981.
17. Veale, D.; Ashcroft, T.; Marsh, C.; Gibson, G.J.; Harris, A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 1987, 55 (5), 513-516.
18. Solbach, C.; Roller, M.; Ahr, A.; Loibl, S.; Nicoletti, M.; et al. Antiepidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int. J. Cancer 2002, 101 (4), 390-394.
19. Koenders, P.G.; Beex, L.V.; Geurts-Moespot, A.; Heuvel, J.J.; Kienhuis, C.B.; Benraad, T.J. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991, 51 (17), 4544-4548.
20. Toi, M.; Hamada, Y.; Nakamura, T.; Mukaida, H.; Suehiro, S.; et al. Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion. Int. J. Cancer 1989, 43 (2), 220-225.
21. Wrba, F.; Reiner, A.; Ritzinger, E.; Holzner, J.H.; Reiner, G. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. an immunohistochemical study. Pathol. Res. Pract. 1988, 183 (1), 25-29.
22. Livasy, C.A.; Reading, F.C.; Moore, D.T.; Boggess, J.F.; Lininger, R.A. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol. Oncol. 2006, 100, 101-106.
23. Huang, S.M.; Harari, P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 1999, 17 (3), 259-269.
24. Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P.W.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997, 3 (4), 515-522.
25. Ching, K.Z.; Ramsey, E.; Pettigrew, N.; D'Cunha, R.; Jason, M.; Dodd, J.G. Expression of Mrna for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol. Cell Biochem. 1993, 126 (2), 151-158.
26. Untawale, S.; Zorbas, M.A.; Hodgson, C.P.; Coffey, R.J.; Gallick, G.E.; et al. Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (Difi) with an amplified epidermal growth factor receptor gene. Cancer Res. 1993, 53 (7), 1630-1636.
27. Yoshida, K.; Kyo, E.; Tsuda, T.; Tsujino, T.; Ito, M.; Niimoto, M.; Tahara, E. EGF and TGF-alpha, the ligands of hyperproduced egfr in human esophageal carcinoma cells, act as autocrine growth factors. Int. J. Cancer 1990, 45 (1), 131-135.
28. Giralt, J.; De Las, H.M.; Cerezo, L.; Eraso, A.; Hermosilla, E.; et al. I. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother. Oncol. 2005, 74 (2), 101-108.
29. Kopp, R.; Rothbauer, E.; Mueller, E.; Schildberg, F.W.; Jauch, K.W.; Pfeiffer, A. reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis. Colon. Rectum. 2003, 46 (10), 1391-1399.
30. Kopp, R.; Ruge, M.; Rothbauer, E.; Cramer, C.; Kraemling, H.J.; Wiebeck, B.; Schildberg, F.W.; Pfeiffer, A. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. 2002, 22 (2B), 1161-1167.
31. Inada, S.; Koto, T.; Futami, K.; Arima, S.; Iwashita, A. Evaluation Of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (P53, E-cadherin, epidermal growth factor receptor). Surg. Today 1999, 29 (6), 493-503.
32. Mukaida, H.; Toi, M.; Hirai, T.; Yamashita, Y.; Toge, T. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991, 68 (1), 142-148.
33. Harris, M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004, 5 (5), 292-302.
34. Sung, M.W.; Nagashima, S.; Johnson, J.T.; Van Dongen, G.A.; Whiteside, T.L. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets. Cell Immunol. 1996, 171 (1), 20-29.
35. Oshimi, Y.; Oshimi, K.; Miyazaki, S. Necrosis and apoptosis associated with distinct ca2+ response patterns in target cells attacked by human natural killer cells. J. Physiol. 1996, 495 (Pt. 2) 319-329.
36. Kettleborough, C.A.; Saldanha, J.; Heath, V.J.; Morrison, C.J.; Bendig, M.M. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991, 4 (7), 773-783.
37. Bier, H.; Hoffmann, T.; Haas, I.; Van, L.A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother. 1998, 46 (3), 167-173.
38. Lo, K-M, Lan, Y, Zhang, X, Wesolowski, J, Brunkhorst, B, Campbell, I.; Gillies, S. The Role of ADCC Effector Function In The Anti-Tumor Activity Of Anti-EGFR antibodies in a mouse xenograft model. Clin. Cancer Res. 2003, 9 (2), A124.
39. Burger, A. M.; Heiss, N. S.; Kreysch, H. G.; Schandelmaier, K.; Wirth, G.; Fiebig, H. H.; Grell, M. The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc. Am. Assoc. Cancer Res. 2003, 44, 1139 (Abstr. 5719).
40. Knecht, R.; Peters, S.; Adunka, O.; Strebhardt, K.; Gstoettner, W.; Hambek, M. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res. 2003, 23 (3B), 2577-2583.
41. Amendt, C.; Mantell, O.; Peters, M.; Yezherlyev, M.; Jauch, K.-W.; Geissler, E.; Bruns, C.J. In vivo activity of humanized monoclonal anti-EGFR antibody EMD 72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model. Proc. Am. Assoc. Cancer Res. 2003, 44, 1434 (Abstr. 6180).
42. Bier, H.; Hoffmann, T.; Hauser, U.; Wink, M.; Ochler, M.; Kovar, A.; Muser, M.; Knecht, R. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 2001, 47 (6), 519-524.
43. Vanhoefer, U.; Tewes, M.; Rojo, F.; Dirsch, O.; Schleucher, N.; et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22 (1), 175-184.
44. Trarbach, T.; Beyer, T.; Schleucher, N.; Stattaus, J.; Mueller, S.P.; et al. A Randomized Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. ASCO Meeting Abstracts. J. Clin. Oncol. 2004, 22 (14 Suppl.), 3018 (Abstr. 3018).
45. Doi, T.; Ohtsu, A.; Saijo, N.; Takiuchi, H.; Ohhashi, Y.; et al. A Phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody "EMD72000 (Matuzumab)" Administered Weekly In Japanese Patients With Advanced Solid Tumors; Safety, PK And PD results of skin biopsies. Abstract No. 3077. ASCO Meeting Abstracts. J. Clin. Oncol. 2005, 23 (16 Suppl.), 211s (Abstr. 3077).
46. Kollmannsberger, C.; Schittenhelm, M.; Honecker, F.; Tillner, J.; Weber, D.; Oechsle, K.; Kanz, L.; Bokemeyer, C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (Matuzumab) in combination with paclitaxel in patients with egfr-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 2006, 17, 1007-1013.
47. 1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in patient with advanced pancreatic cancer. Br. J. Cancer 2006, 94, 1293-1299.
48. Rao, S.; Starling, N.; Benson, M.; Massey, A.; Wotherspoon, A.; et al. Phase I study of the humanized epidermal growth factor receptor (egfr) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. ASCO Meeting Abstracts. J. Clin. Oncol. 2005, 23(16 Suppl.), 314s. (Abstr. 4028).
49. Salazar, R.; Tabernero, J.; Rojo, F.; Jimenez, E.; Montaner, I.; et al. Dose-Dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (Mab) EMD 72000 administered every three weeks (Q3w). a phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). ASCO Meeting Abstracts. J. Clin. Oncol. 2005, 23, 127s. (Abstr. 2002).
50. Tabernero, J.; Rojo, F.; Jimenez, E.; Montaner, I.; Santome, L.; et al. A phase I PK And serial tumor and skin pharmacodynamic (PD) study of weekly (Q1w), every 2-week (Q2w) or every 3-week (Q3w) 1-hour (H) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (Pt) with advanced tumors. ASCO Meeting Abstracts. 2003, 22, 192. (Abstr. 770).
51. Tillner, J.; Golob, M.; Vanhoefer, U.; Tabernero, J.; Rosen, O.; Kovar, A. Pharmacokinetics (PK) of the novel humanized anti-EGFR Mab EMD 72000. Clin. Cancer Res. 2003, 9 (2), A110.
52. Trarbach, T.; Schleucher, N.; Weber, D.; Tillner, J.; Fassmann, I.; Seeber, S.; Vanhoefer, U. Phase I study of the humanized antiepidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (Pts) with advanced esophago-gastric (EG) adenocarcinoma. ASCO Meeting Abstracts. J. Clin. Oncol. 2005, 23 (16 Suppl.), 230s. (Abstr. 3156).
53. Blohmer, J.; Gore, M.; Kuemmel, S.; Verheijen, R.H.; Kimmig, R.; et al. Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer. ASCO Meeting Abstracts. J. Clin. Oncol. 2005, 23 (16 Suppl.), 174s (Abstr. 2534).
54. Seiden, M.; Burris, H.A.; Matulonis, U.; Hall, J.; Armstrong, D.; et al. A phase II trial of EMD72000 (Matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced mullerian malignancies. Gynecol. Oncol. 2007, 104, 727-731.
55. Baselga, J.; Pfister, D.; Cooper, M.R.; Cohen, R.; Burtness, B.; et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18 (4), 904-914.
56. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 1997, 3 (12), 2703-2707.
57. Raben, D.; Helfrich, B.; Chan, D.C.; Ciardiello, F.; Zhao, L.; et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 2005, 11 (2 Pt. 1), 795-805.
58. Herbst, R.S.; Langer, C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 2002, 29 (1 Suppl. 4), 27-36.
59. Saltz, L.B.; Meropol, N.J.; Loehrer, P.J.; Sr.; Needle, M.N.; Kopit, J.; Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22 (7), 1201-1208.
60. Robert, F.; Blumenschein, G.; Herbst, R.S.; Fossella, F.V.; Tseng, J.; Saleh, M.N.; Needle, M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J. Clin. Oncol. 2005, 23 (36), 9089-9096.
61. Lenz, H.; Mayer, RJ.; Gold, P.; Mirtsching, B.; Cohn, A.L.; Pet al. Activity Of Erbitux (cetuximab) in patients with colorectal cancer refractory to a fluoropyrimidine, irinotecan, and oxaliplatin. Proc. ASCO Gastro Intestinal Cancers Symp. 2005. (Abstr. 225).
62. Vermorken, J.; Bourhis, J.; Trigo, J.; Kies, M.; Leon, X.; et al. Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. ASCO Meeting Abstracts 2005, 23 (16S), 501S (Abstr. 5505).
63. Physicians' Desk Reference, 60th Ed. Montvale, NJ: Thomson PDR, 2006; 937-940.
64. Thienelt, C.D.; Bunn, P.A.; Jr.; Hanna, N.; Rosenberg, A.; Needle, M.N.; Long, M.E.; Gustafson, D.L.; Kelly, K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 2005, 23 (34), 8786-8793.
65. Kollmannsberger, C.; Schittenhelm, M.N.; Honecker, F.; Tillner, J.; Weber, D.; Oechsle, K.; Kanz, L.; Bokemeyer, C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 2006, 17, 1007-1013.
66. Yang, X.D.; Jia, X.C.; Corvalan, J.R.F.; Wang, P.; Davis, C.G.; Jakobovits, A. eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer Res. 1999, 59 (6), 1236-1243.
67. Bush, T.; Freeman, D.; Ogbagabriel, S.; Belmontes, B.; Kozlosky, C.; Baher, A.; et al. Activity of panitumumab alone and in combination with chemotherapy againstmutant epdermal growth factor receptor (egfr)-expressing non-small cell lung carcinoma (NSCLC) cell lines and xenografts. AACR-NCI-EORTC Annual Meeting. 2005, 141-142.
68. Crawford, J.; Sandler, A.B.; Hammond, L.A.; Schiller, J.; Belani, C.; et al. ABX-EGF In combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2004, 22 (14 Suppl.), 7083.
69. Rowinsky, E.K.; Schwartz, G.H.; Gollob, J.A.; Thompson, J.A.; Vogelzang, N.J.; et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 2004, 22 (15), 3003-3015.
70. Peeters, M.; Van Cutsem, E.; Siena, S.; Humblet, Y.; Hendlisz, A.; et al. A Phase 3, Multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (Mcrc). Presentation At: Annual Meeting Of The American Association For Cancer Research; April 1-5, 2006; Washington, DC; 2006.
71. Hecht, J.R.; Mitchell, E.; Baranda, J.; Malik, I.; Richards, D.; Navale, L.; D'Avirro, P.; Amado, R. Panitumumab Antitumor Activity In Patients (pts) with metastatic colorectal cancer (Mcrc) expressing low (1-9%) Or Negative (.1%) levels of epidermal growth factor receptor (EGFR). Poster Presented At: Annual Meeting Of The American Society Of Clinical Oncology; June 2-6, 2006; Atlanta, GA; 2006.
72. Berlin, J.; Neubauer, M.; Swanson, P.; Harker, W.G.; Burris, H.; Hecht, J.R.; Navale, L.; Brown, J.; Amado, R. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (Mcrc) Expressing >/= 10% epidermal growth factor receptor (EGFR). Poster Presented At: Annual Meeting Of The American Society Of Clinical Oncology; June 2-6, 2006; Atlanta, GA; 2006.
73. Weiner, L.M.; Belldegrun, A.; Rowinsky, E.; Crawford, J.; Lockbaum, P.; et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. Abstract 3059. J Clin Oncol (Meeting Abstracts). 2005, 23 (16 Suppl.), 3059.
74. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351 (4), 337-345.
75. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Cohen, R.B.; et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J. Clin. Oncol. 2004, 22 (14 Suppl.), 489s. (Abstr. 5507).
76. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.L.; Van Laethem, J.L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25, 1658-1664.
77. Arends, R.; Yang, B.B.; Schwab, G.; Lockbaum, P.; Funelas, C.; Roskos, L. Flexible dosing schedules of panitumumab (ABXEGF) in cancer patients. J Clin Oncol (Meeting Abstracts). 2005, 23 (16 Suppl.), 3089.
78. Hecht, J.R.; Patnaik, A.; Malik, I.; Venook, A.; Berlin, J.; et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (Mcrc): an updated analysis. J. Clin. Oncol. (Meeting Abstracts) 2004, 22 (14 Suppl.), 3511.
79. Sunada, H.; Magun, B.E.; Mendelsohn, J.; Macleod, C.L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 1986, 83 (11), 3825-3829.
80. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [Corrected]. J. Clin. Oncol. 2003, 21 (12), 2237-2246.
81. Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J.; Jr.; Prager, D.; et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A Randomized Trial. JAMA 2003, 290 (16), 2149-2158.
82. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350 (21), 2129-2139.
83. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304 (5676), 1497-1500.
84. Bell, D.W.; Lynch, T.J.; Haserlat, S.M.; Harris, P.L.; Okimoto, R.A.; et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005, 23 (31), 8081-8092.
85. Cappuzzo, F.; Hirsch, F.R.; Rossi, E.; Bartolini, S.; Ceresoli, G.L.; et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97 (9), 643-655.
86. Shepherd, F.A.; Pereira, J.; Ciuleanu, T.E.; Tan, E.H.; Hirsh, V.; et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. a National Cancer Institute Of Canada Clinical Trials Group (NCIC CTG) trial. J. Clin. Oncol. (Meeting Abstracts). 2004, 22 (14 Suppl.), 7022.
87. Tsao, M.S.; Sakurada, A.; Cutz, J.C.; Zhu, C.Q.; Kamel-Reid, S.; et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353 (2), 133-144.
88. Hirsch, F.R.; Bunn, P.A.; Jr. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J. Clin. Oncol. 2005, 23 (36), 9044-9047.
89. Shepherd, F.A.; Rodrigues, P.J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353 (2), 123-132.
90. Perez-Soler, R.; Chachoua, A.; Hammond, L.A.; Rowinsky, E.K.; Huberman, M.; et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol. 2004, 22 (16), 3238-3247.
91. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A.; Jr.; Di Maria, M.V.; Veve, R.; et al Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003, 21 (20), 3798-3807.
92. Cappuzzo, F.; Hirsch, F.R.; Rossi, E.; Bartolini, S.; Ceresoli, G.L.; et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97 (9), 643-655.
93. Hirsch, F.R.; Varella-Garcia, M.; Mccoy, J.; West, H.; Xavier, A.C.; et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J. Clin. Oncol. 2005, 23 (28), 6838-6845.
94. Cappuzzo, F.; Toschi, L.; Trisolini, R.; Bemis, M.; Sujita, M.; et al. Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): preliminary results of the ONCOBELL trial. Abstract 7023. ASCO Meeting Abstracts 24. 2006.
95. Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.; et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 2004, 22 (5), 777-784.
96. Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 2004, 22 (5), 785-794.
97. Herbst, R.S.; Prager, D.; Hermann, R.; Miller, V.; Fehrenbacher, L.; et al. TRIBUTE - A Phase III trial of erlotinib hcl (OSI-774) Combined With Carboplatin And Paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts). 2004, 22 (14 Suppl.), 7011.
98. Gatzemeier,U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2004, 22 (14 Suppl.), 7010.
99. Busam, K.J.; Capodieci, P.; Motzer, R.; Kiehn, T.; Phelan, D.; Halpern, A.C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 2001, 144 (6), 1169-1176.
100. Van, D.R.; Kirtschig, G.; Scheffer, E.; Stoof, T.J.; Giaccone, G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br. J. Dermatol. 2002, 147 (3), 598-601.
101. Perez-Soler, R.; Saltz, L. Cutaneous Adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 2005, 23 (22), 5235-5246.
102. Burtness, B.; Goldwasser, M.A.; Flood,W.; Mattar, B.; Forastiere, A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005, 23 (34), 8646-8654.
103. Mita, A.C.; De Jonge, M.; Verweij, J.; Papadopoulos, P.; Schwartz, G.K.; et al. Erlotinib (Tarceva) dosing-to-rash: preliminary results of a pilot phase ii intra-patient dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) study of E in previously treated patients with advanced non-small cell lung cancer (NSCLC). AACR-NCI-EORTC International Conference - Molecular Targets and Cancer Therapeutics. Clin. Cancer Res. 2005, 11 (24, Part 2), 9061s. (Abstr. B118). 2005, 156.